Pipeline - Trovagene

Providing New Treatment Options Across a
Wide Array of Cancers

Demonstrated synergy of onvansertib in combination with already
approved chemotherapies and targeted therapeutics

Pipeline within a Molecule

We are developing onvansertib as part of a combination regimen across a variety of cancers and integrating a predictive clinical biomarker strategy to identify patients who are most likely to respond to treatment. The opportunity to bring new treatment options to patients in indications where there is a high medical need we believe presents significant market opportunities.

Preclinical
Phase 1
Phase 2
Acute Myeloid Leukemia – Orphan Drug Designation in the U.S. and Europe
Phase 1b/2 trial in combination with low-dose cytarabine (LDAC) or decitabine
Leukemias & Lymphomas
Metastatic Castration-Resistant Prostate
Phase 2 trial in combination with Zytiga® (abiraterone acetate)/prednisone
Colorectal (CRC)
Lung
Ovarian
Others (adrenocortical, sarcomas, head and neck, skin, liver, pancreatic, ampullary)
Solid Tumor Cancers
Triple Negative Breast
A Phase 1 trial has been completed in advanced or metastatic solid tumor cancers, including colorectal, lung, and ovarian, and published in Investigational New Drugs in 2017

Recent News

Feb 28, 2019

Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of …

Feb 14, 2019

Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of …

Jan 29, 2019

Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of …